Kommuniké från extra bolagsstämma i RLS Global AB (publ)

RLS Global AB (publ) höll under måndagen den 19 augusti 2019 extra bolagsstämma varvid följande huvudsakliga beslut fattades. För mer detaljerad information om innehållet i besluten hänvisas till pressmeddelande som offentliggjordes den 29 juli 2019 och den fullständiga kallelsen till stämman. Kallelse till extra bolagsstämma samt fullständiga förslag avseende stämmans beslut enligt nedan finns tillgängliga på bolagets hemsida:

https://rls.global/invitations/

Read More


Settlement with Karin Bergqvist

RLS Global AB has reached a settlement with Dr. Karin Bergqvist, who is one of the two inventors of ChloraSolv. Dr. Bergqvist had taken legal action against RLS Global AB, claiming additional compensation for
her earlier assignment of her rights to the invention of ChloraSolv.

Read More


RLS Global AB (PUBL) – Annual Report 2018

RLS Global's Annual Report 2018 is available in English from today, April 30th, 2019, on the company's website, Annual Report.

Read More


RLS Global AB (publ) Interim Report Q1 2019

RLS Global AB (publ) Interim Report Q1 2019
RLS Global AB (publ)
Interim Report Q1 2019

Read More


ChloraSolv receives CE marking

Gothenburg, Sweden, April 10th, 2019 – RLS Global AB announces that ChloraSolv, its wound care product targeting diabetic foot ulcers, has successfully obtained a CE marking based on confirmation from Lloyd’s Register, acting as Notified Body, and is therefore cleared in 32 European countries for commercialization.

Read More


Year-end report 2018

Intensified work with ChloraSolv.

JANUARY−DECEMBER 2018

Net sales amounted to SEK 2.6 million (2.3), a revenue growth of 12.1 percent.
Earnings before interest...

Read More